Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NSA2 pseudogene 4 is a predicted non-coding pseudogene derived from the sequence of the NSA2 gene, which encodes a conserved nucleolar protein involved in ribosomal subunit biogenesis[3]. Pseudogenes such as NSA2P4 contain sequence similarity to their parental genes but lack protein-coding function due to mutations, deletions, or regulatory element absence[5]. Recent research suggests that some pseudogenes can exert regulatory control over their parental genes by producing antisense transcripts or small RNAs that modulate gene expression or epigenetic state[1][2][5]. However, NSA2P4 itself is not a receptor or a classic drug target, and there is no evidence for its direct role in disease, drug interaction, or biomarker utility. In summary, NSA2P4 is a non-coding pseudogene without therapeutic targeting relevance, and its functional or disease connections remain largely unexplored. The entry is primarily notable for being a pseudogene; it is not itself a receptor, protein, or a targetable entity in pharmacology or molecular medicine.
Not applicable; pseudogenes do not encode proteins and are not direct drug targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NSA2 pseudogene 4 (NSA2P4).